There is no tailored therapy yet for human basal-like mammary carcinomas.
Introduction
Topotecan is used to treat ovarian, cervical and small cell lung cancer patients.
Topotecan inhibits topoisomerase I (Top1)-mediated religation of single-stranded DNA breaks (SSBs). When drug-stabilized covalent Top1-DNA complexes cause stalling of the replication machinery, SSBs are converted into double-stranded DNA breaks (DSBs). Such replication-mediated DSBs appear to be the primary cytotoxic mechanism of Top1 inhibitors in dividing cells (1) . Cell lines defective in proper DSB repair pathways show an increased sensitivity to Top1 poisons (reviewed in (1) ).
An example is a defect in BRCA1 (2) , which is required for error-free repair of DSB by homologous recombination (HR). HR is frequently impaired in basal-like breast cancer, and BRCA1 dysfunction is one of the causes of this defect (3) (4) (5) . About 15% of clinical patients are diagnosed with basal-like breast cancer, which is usually negative for ERBB2 and hormone receptors ("triple negative") (6, 7) . Patients with this disease face a poor prognosis, as there is no targeted therapy available (6, 7) . Topotecan is not applied in the clinic to breast cancer patients; hence, we have investigated in a mouse model whether the use of this Top1 inhibitor is an alternative therapeutic approach for patients with basal-like breast cancer. We used the K14cre;Brca1 ;p53 -/-mammary adenocarcinomas arise, that recapitulate key features of human BRCA1-associated breast cancer (invasive ductal carcinoma not otherwise specified) and can be transplanted orthotopically into syngeneic mice without loss of their genomic profile, morphology or sensitivity to drug (8, 9) . In this model ;p53 -/-tumor cells and a strong increase in overall survival (10) .
Remarkable responses to olaparib treatment with only few adverse effects were also observed in a phase I clinical trial with patients that carry BRCA1 or BRCA2 mutations (11) . Since in our model olaparib treatment alone did not result in tumor eradication (10), we have tested whether increasing the induction of SSBs by a Top1
poison would enhance anti-tumoral efficacy of this PARP inhibitor.
Here we demonstrate that topotecan alone or in combination with olaparib may be another therapeutic option for breast cancer patients who carry cancers with HR defects. However, we find that Brca1 
Materials and Methods
Animals, generation of (Abcg2-deficient) mammary tumors and orthotopic transplantation of tumor fragments into syngeneic wild-type mice
Brca1
-/-;p53 -/-mammary tumors were generated and genotyped as described (8 5'-CAGTCGATGGATCCACTTAGG-3'). Orthotopic transplantations, mammary tumor measurements and sampling were performed as explained previously (9) . All experimental procedures were approved by the Animal Ethics Committee of the Netherlands Cancer Institute.
Drugs and treatment of tumor-bearing animals
Topotecan was dissolved in glucose (5%, w/v) to yield a solution of 0.4 mg/ml (of active compound) and administered at 10 µl/g of body weight by i.p. injection. were continued after a recovery time of 9 days following the last treatment.
Olaparib and tariquidar were applied as reported (10, 17) . In topotecan-olaparib combination-treated animals the topotecan dose was lowered 8-fold to 0.5 mg/kg and administered on days 0-4, 14-18 and 28-32, whereas 50 mg olaparib per kg was injected i.p. daily for 42 days and, when combined with topotecan, given 15 min after topotecan injection. 2 mg tariquidar per kg was administered i.p. every second day during this 42 day period.
Genome-wide expression profiling
RNA extraction, amplification, microarray hybridization, data processing and statistical analyses were performed as described (9 
Multiplex ligation-dependent probe amplification (MLPA) analysis
(RT-)MLPA analyses on tumor DNA or RNA were carried out as before (9, 17) .
Immunohistological analysis
Immunohistochemical stainings were performed as described (10) . ABCG2 was probed with the rat anti-mouse monoclonal (BXP53) from Abcam (ab24115, 1:400) and detected with a biotinylated rabbit anti-rat secondary antibody (Dakocytomation, # E0468, 1:100).
Tumor protein extraction and topoisomerase I immunoblotting
Snap-frozen tumor samples were ground into a fine powder by pestle in a liquid nitrogen cooled mortar and transferred into 1. In drug-sensitive tumors we identified a strong increase in nuclear DNA damage foci 24 hours after a 5 day topotecan schedule using γ-H2AX as marker (Supplementary Figure 2) . γ-H2AX foci are associated with DSBs (18), hence our finding supports the notion that topotecan-induced SSBs are converted into DSBs in the tumors. Moreover, we observed a significant decrease in the proliferation marker Ki-67 and an increase in senescense-associated β-galactosidase activity as well as increased nuclear p19 ARF staining (Supplementary Figure 3) after topotecan treatment. On the basis of published findings in cell lines (19) we expected to find 
Results

Brca1
Abcg2 is frequently upregulated in topotecan-resistant tumors
We looked for alterations in gene expression using a two-class paired Significance of Microarray Analysis (SAM) comparing 39K oligo expression arrays of resistant to matched untreated control tumor samples. We found elevated expression of 150
genes at a delta of 1.058 (false discovery rate of 2.21%, Figure 2 , A and Supplementary Table 2 ). Of these 150 genes only Abcg2 has previously been linked to topotecan resistance. Abcg2 encodes the ATP-binding cassette (ABC) drug efflux transporter ABCG2/BCRP, which is known to cause topotecan resistance in cultured cells (20, 21) . Quantification of Abcg2 transcript levels confirmed that the level of Abcg2 and accordingly their resistant phenotype after transplantation, but were completely sensitive to topotecan. This shows that upregulation of the mouse P-glycoproteins by itself does not lead to topotecan resistance in this tumor model.
Introduction of Abcg2 null alleles into the mouse model
To study ABCG2-independent topotecan resistance mechanisms, Abcg2 null alleles were introduced into the K14cre,Brca1 
ABCG2-independent mechanisms of topotecan resistance
Alterations of the drug target Top1 result in camptothecin resistance in cultured cells (12, 13, 25) . Several point mutations, which disable camptothecin(analogue)- 
Discussion
We show here that spontaneous and transplanted Brca1 of their matched untreated controls (Figure 1, C) . Such intertumoral differences, which did not correlate with a specific histomorphology, were also observed with other drugs in this model (9, 10) and seem to mimic the response heterogeneity seen in patients. We know that tumors differ in additional mutations acquired after the initial Brca1 and p53 deletion (8), and these must be responsible for response variability.
Despite their initial sensitivity, tumors eventually acquire resistance to the MTD of topotecan. Research with cell lines has identified several mechanisms of camptothecin/topotecan resistance. These include overexpression of the drug efflux transporters ABCG2, ABCC4, ABCB1, ABCC2, reduced expression of Top1, Top1 mutations, Top1 mis-localization, elevated DNA repair and resistance to apoptosis (reviewed in (1, 12, 13) ). Which of these mechanisms contribute to topotecan resistance in real tumors has remained unclear, however (34, 35). We show here that increased levels of ABCG2 are a major mechanism of topotecan resistance in vivo, as in cultured cells (21, 36, 37) . The importance of this mechanism is illustrated by the In any case, our data show that in vivo imaging of apoptosis is not a suitable readout for therapy-response in this tumor model.
To explore new therapeutic alternatives for breast cancers associated with BRCA1 defects, we tested the combination of topotecan with the PARP inhibitor olaparib.
This combination did not result in tumor eradication, even if we prevented efflux of topotecan by using Abcg2 -/-tumors and P-glycoprotein-mediated olaparib extrusion by inhibiting this transporter with tariquidar. We also observed this lack of complete cell kill when olaparib was combined with platinum drugs (10) . It is clinically relevant that the topotecan-olaparib combination proved so toxic in mice that we had to reduce the topotecan concentration 8-fold. We have not seen this increased toxicity in the combination of olaparib with cisplatin or carboplatin (10). We do not think that topotecan toxicity is increased because olaparib inhibits ABCG2, since methotrexate transport by ABCG2-overexpressing cells was not altered by olaparib (data not shown). It seems more likely that the level of endogenous DNA damage requiring PARP-mediated repair is already close to the maximum that normal cells can deal with. A further increase in single-strand DNA breaks induced by topotecan, would overtax the DNA repair capacity remaining in the absence of functional PARP.
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